Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
23
|
| pubmed:dateCreated |
1992-9-10
|
| pubmed:abstractText |
The mechanism of FK506 immunosuppression has been proposed to proceed by formation of a tight-binding complex with the intracellular 12-kDa FK506-binding protein (FKBP12). The FK506-FKBP12 complex then acts as a specific high-affinity inhibitor of the intracellular protein phosphatase PP2B (calcineurin), interrupting downstream dephosphorylation events required for T-cell activation. Site-directed mutagenesis of many of the surface residues of FKBP12 has no significant effect on its affinity for calcineurin. We have identified, however, three FKBP12 surface residues (Asp-37, Arg-42, and His-87) proximal to a solvent-exposed segment of bound FK506 that may be direct contacts in the calcineurin complex. Site-directed mutagenesis of two of these residues decreases the affinity of FKBP12-FK506 for calcineurin (Ki) from 6 nM for wild-type FKBP12 to 3.7 microM for a R42K/H87V double mutant, without affecting the peptidylprolyl isomerase activity or FK506 affinity of the mutant protein. These FKBP12 mutations along with several substitutions on FK506 known to affect calcineurin binding form a roughly 100-A2 region of the FKBP12-FK506 complex surface that is likely to be within the calcineurin binding site.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Calcineurin,
http://linkedlifedata.com/resource/pubmed/chemical/Calmodulin-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphoprotein Phosphatases,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus Binding Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0021-9258
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
267
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
16029-32
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:1379588-Amino Acid Sequence,
pubmed-meshheading:1379588-Animals,
pubmed-meshheading:1379588-Binding Sites,
pubmed-meshheading:1379588-Calcineurin,
pubmed-meshheading:1379588-Calmodulin-Binding Proteins,
pubmed-meshheading:1379588-Carrier Proteins,
pubmed-meshheading:1379588-Humans,
pubmed-meshheading:1379588-Models, Molecular,
pubmed-meshheading:1379588-Molecular Conformation,
pubmed-meshheading:1379588-Molecular Sequence Data,
pubmed-meshheading:1379588-Molecular Weight,
pubmed-meshheading:1379588-Mutagenesis, Site-Directed,
pubmed-meshheading:1379588-Phosphoprotein Phosphatases,
pubmed-meshheading:1379588-Protein Conformation,
pubmed-meshheading:1379588-Sequence Homology, Nucleic Acid,
pubmed-meshheading:1379588-Structure-Activity Relationship,
pubmed-meshheading:1379588-Tacrolimus,
pubmed-meshheading:1379588-Tacrolimus Binding Proteins
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex.
|
| pubmed:affiliation |
Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139-4211.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|